In this Review:
Pembrolizumab for previously treated advanced NSCLC
Atezolizumab for locally advanced or metastatic PD-L1-selected NSCLC
Nivolumab vs docetaxel in advanced non-squamous NSCLC
Health status in nivolumab patients with advanced squamous NSCLC
Atezolizumab vs docetaxel in NSCLC stratified by PD-L1 status
Routine lung cancer genotyping in Germany
New therapies vs everolimus in advanced RCC: nivolumab (CheckMate 025) and cabozantinib (METEOR)
Everolimus in advanced non functional NETs (RADIANT-4)
177-Lu-Dotatate in patients with midgut NETs (NETTER-1)
Please login below to download this issue (PDF)